Pt Prodia Widyahusada Tbk · IDX:PRDA
Pt Prodia Widyahusada Tbk — Q1 2017 Earnings Presentation
32 slides from Pt Prodia Widyahusada Tbk's earnings presentation, Apr 28, 2017
Slide 1: PT Prodia Widyahusada Tbk 2017 Q1 Results Update
CONFIDENTIAL PT Prodia Widyahusada Tbk 2017 Q1 RESULTS UPDATE 28 April 2017
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation relating to the Company. The information contained in this presentation is strictly confidential and is provided to you solely for your reference. By vie
Slide 3: Agenda
confidential AGENDA 1 INVESTMENT HIGHLIGHTS 2 Q1 2017 BUSINESS UPDATE 3 2017 GROWTH STRATEGIES 4 FINANCIAL HIGHLIGHTS 3
Slide 4: Investment Highlights
confidential 1 INVESTMENT HIGHLIGHTS 2 Q1 2017 BUSINESS UPDATE 3 2017 GROWTH STRATEGIES 4 FINANCIAL HIGHLIGHTS 4
Slide 5: Key Business Highlights
confidential Key Business Highlights
Slide 6: PRODIA is at Forefront of Significant Indonesian Healthcare Opportunity
confidential 1. PRODIA is at Forefront of Significant Indonesian Healthcare Opportunity Total Indonesia Healthcare Expenditure Significant Long-term Growth Potential (In USD bn) A Population of 256 million – 4th Largest Worldwide (3) Rapidly expanding middle class 29.0 Strong GDP growth 27.6 2
Slide 7: Significant Growth Potential for Private Laboratories in Indonesia
1. Significant Growth Potential for Private Laboratories in confidential Indonesia Indonesian Healthcare Market is Growing Private Laboratory Testing Market is Growing Faster (Market size by revenue; In USD bn) (Market size by revenue; In USD mn) 13A-15E CAGR (0.3%) 817 29 28 27 27 26 706 25 24 615
Slide 8: Indonesian Pioneer in Clinical Laboratory Testing
2. Indonesian Pioneer in Clinical Laboratory Testing Received SMK3 accreditation and OHSAS 2015, along with the Award as "Diagnostic Services Company of the Year 2015" from Frost & Sullivan Opened the first green building used for laboratories in Established professional Indonesia, Graha Prodi
Slide 9: Largest Nationwide Network
confidential 3. Largest Nationwide Network I II Clinical Specialty POC Hospital VII Clinical PHC POC Clinical POC Labs Clinic Outlet Lab Labs Clinic Outlet Labs Outlet 129 Clinical Labs 15 0 2 1 7 1 6 5 1 and 1 and PHC I Kalimantan V VIII II Sulawesi Clinical POC Hospital Labs Outlet Lab 118 POC Out
Slide 10: Scalable Hub and Spoke Model
confidential 3. Scalable “Hub and Spoke” Model Prodia Clinical Labs, Hospital Centralized information and Other Clinics refer tests to Prodia National with integrated IT “Hub and spoke” model offers Reference Lab PNRL (PNRL) platform that connects scalable platform reducing each lab to PNRL tu
Slide 11: Most Recognized Clinical Lab Brand in Indonesia
confidential 4. Most recognized Clinical Lab Brand in Indonesia The only clinical lab in Indonesia accredited by College of American Pathologists Pioneer in Indonesian Laboratory Services (“CAP”(3)) Received 56% of the votes from a sample of Center of Excellence Indonesian consumers in the 2015
Slide 12: Comprehensive Service Offering – Target Multiple Customer Segments
confidential 5. Comprehensive Service Offering –Target Multiple Customer Segments
Slide 13: PRODIA Most Recognized Clinical Lab brand
confidential 5. PRODIA Most Recognized Clinical Lab brand Corporate Indonesia Indonesia Best Top Brand Award Image Award Original Brand Brand Award 2009 - 2016 (IMAC) (IOB ) 2012 - (IBBA) 2012 - 2016 2016 2013 - 2016 2016 Service Quality Award 2015 - 2016 2013, 2015 - 2016 Rekor Bisnis 2013 Satria B
Slide 14: Senior Leadership and Management Team
confidential 7.Senior Leadership and Management Team Diagnostic Services Best Brand Gold Company of the Year 2015 2015 - Frost & Sullivan - IBBA Awards Drs. Gunawan Dr. Endang Scott Andrew Joseph Dr. Andi Prawiro Soeharto Hoyaranda Merrillees F. P, Luhukay Wijaya, MBA Co-Founder and Co-Founder and C
Slide 15: Pioneer and Leader in Indonesian Independent Clinical Lab Industry
Pioneer 2 and Pioneer Leader ininIndonesian and Leader Independent Indonesian Independent Clinical Lab Industry confidential Clinical Lab Industry No.1 Independent Clinical Lab Chain Largest and Most Diversified Laboratory Network Market Share by Revenue of Key Players (2015) Number of Labs of 6 Key
Slide 16: Q1 2017 Business Update
confidential 1 INVESTMENT HIGHLIGHTS 2 Q1 2017 BUSINESS UPDATE 3 2017 GROWTH STRATEGIES 4 FINANCIAL HIGHLIGHTS 17
Slide 17: Q1 2017 Outlets Development
confidential Q1 2017 Outlets Development Clinical Labs Point-of-Care (POC) Specialty Clinics Hospital Labs & PHCs Outlets Equipped to conduct Specialized facilities and process certain Consists of both POC focusing on particular Operate hospital labs routine tests Centers and POC fields of medic
Slide 18: PWHC-First Indonesian Personalized Medicine for Women
confidential PWHC-First Indonesian Personalized Medicine for Women Prodia Women Health Centre spesifically for women, is based on the concept of Women’s-Wellness and is the first in Indonesia that utilizes the latest diagnostic technology based on individual personalized treatment (Personalized Medi
Slide 19: Q1 2017 New Testing Types and Recognition Award
Q1 2017 New TESTING TYPES Molecular Immunology Urinalysis • CT/NG RT PCR • Mutation of • Fragmentation • Aldosteron JAK2 V617 of DNA Sperm Q1 2017 Recognition Award Master Service Award Wow Brand Award 2012 - 2017 2015 & 2017
Slide 20: Technology to increase customer satisfaction
Technology to increase customer satisfaction Launched e-Pay and e-Reg to increase distribution channel and provide easier way to register and payment system Payment can be made through ATM Transfer and Credit Card Customers can access their laboratory results through PRODIA apps and email
Slide 21: Q1 2017 Results
confidential Q1 2017 Results Financial Q1 2016 Q1 2017 Revenue (IDR Bn) 311.38 331.57 ▲ 6.5% EBITDA (IDR Bn) 50.04 52.15 ▲ 4.2% EBITDA Margin 16.1% 15.7% ▼ 40 bps Net Income (IDR Bn) 24.16 32.31 ▲ 33.73% Upgrade Clinical Lab to PHC 4 • No of visits (mn) POCs 9 -2 =7 • Revenue per visit (IDR 000) • H
Slide 22: 2017 Growth Strategies
confidential 1 INVESTMENT HIGHLIGHT 2 Q1 2017 BUSINESS UPDATE 3 2017 GROWTH STRATEGIES 4 FINANCIAL HIGHLIGHT 25
Slide 23: Growth Strategies
confidential Growth Strategy Growth Strategies A Near-term 1 Expand our presence and grow our network of outlets in both existing and new markets in Indonesia 2 Upgrade existing clinical laboratories to provide wider range of tests and services and increase volume 3 Enhance internal operating effici
Slide 24: Near Term Growth Plan
confidential NEAR Term Growth Plan Prodia’s Network Expansion Plan in Five Years 1 2 Expand Network of Outlets Upgrade Clinical Labs Upgrade up to 39 additional clinical labs to 4 regional reference labs(1) PHC Clinics(3) Up to 33 additional clinical labs over next five years 24 Clinical Lab Improve
Slide 25: Leader in Next Generation Technology
Leader in Next Generation Technology confidential (Long-term Strategy) Immunology Laboratory Platforms Molecular Diagnostics (Flow Cytometry) Lab Innovation Diversified Clinical Diagnostics Platform + Scientific Talent Chromatography-Mass Advanced Pathology Lab Spectrometry The Concept of Precision
Slide 26: Financial Highlights
confidential 1 INVESTMENT HIGHLIGHTS 2 Q1 2017 BUSINESS UPDATE 3 2017 GROWTH STRATEGIES 4 FINANCIAL HIGHLIGHTS 29
Slide 27: Q1 2017 Revenue & EBITDA
confidential Q1 2017 Revenue & EBITDA (unaudited Report) Revenue EBITDA In IDR bn In IDR bn 1,198 175 1,081 986 148 132 16.1% 15.7% 13.7% 14.6% 13.4% 311 332 50 52 2013 2014 2015 Q1 2016 Q1 2017 2013 2014 2015 Q1 2016 Q1 2017 Revenue growth of 6.5% driven by revenue/visit increased by 10.4% EBIT
Slide 28: Q1 2017 Gross Profit and Net Income
confidential Q1 2017 Gross Profit and Net Income (unaudited Report) Gross Profit Net Income In IDR bn In IDR bn Net Income 32 192 182 24 57.9% 58.3% 9.7% 7.8% Q1 2016 Q1 2017 Q1 2016 Q1 2017 Improvement of 40 bps in Gross Profit driven by decreasing of direct cost and indirect cost percentage of t
Slide 29: Q1 2017 Cost Structure
confidential Q1 2017 Cost Structure (unaudited Report) Cost of Revenues (In IDR bn) 42.7% 42.0% 41.7% 42.1% 511 454 384 82 72 47 337 140 382 429 130 23 24 38.9% 107 115 2013A 2014A 2015A Q1 2016 A Q1 2017 A Indirect Cost Direct Cost Cost of Revenues as % of Total Revenue Operating Expenses (In IDR b
Slide 30: Liabilities & Equity
confidential Liabilities & Equity (Unaudited Report) Q12016 Q12017 % Liabilities (IDR bn) Current Liabilities 137.06 166.78 21.7% Total Liabilities 228.43 541.58 137.1% Total Equity 522.32 1,295.85 148.1% Total Liabilities and Equity 750.76 1,837.43 144.7%
Slide 31: Share Holder
Share Holder confidential No.1 clinical lab chain in Indonesia(1) Premium clinical laboratory brand Dominant and industry pioneer PT. PRODIA WIDYAHUSADA TBK Nationwide Outlet Network across Indonesia PT. Prodia Utama Bio Majesty Pte. Ltd Public 57% 18% 25.0% 35
Slide 32: Thank You
SG Li Rid for Quality THANKYOU
PT Prodia Widyahusada — Q1 2017 Earnings Presentation on 6ix